News
Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...
Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback